Key result
Abnormal Tc-99m sestamibi GSPECT independently predicted cardiac events in asymptomatic ESRD patients on hemodialysis (HR 46.1; 95% CI 7.1-46.7; P<0.001).
Why the study?
Does Tc-99m sestamibi GSPECT predict cardiac events in asymptomatic ESRD patients on hemodialysis?
Population
41 asymptomatic end-stage renal disease patients undergoing hemodialysis for 12 months or less with…
Comparison
Tc-99m sestamibi myocardial perfusion gated… vs 20 individuals matched for age, sex, and BMI…
Design
Cohort
Follow-up
2 years
Authors
Loading...
May support GSPECT risk stratification in asymptomatic ESRD; leaves open whether screening alters catheterization or transplant outcomes.
Cohort (n=61)
Does Tc-99m sestamibi GSPECT predict cardiac events in asymptomatic ESRD patients on hemodialysis?
Hazard Ratio: 46.1 (95% CI 7.1–46.7)
Absolute Event Rate: 54% vs 0%
p-value: p=<0.001
Tc-99m sestamibi GSPECT provides excellent risk stratification and prediction of cardiac events in asymptomatic ESRD patients on hemodialysis, which may help guide decisions for catheterization and renal transplantation.
Amin et al. (2013) conducted a cohort in end-stage renal disease (n=61). Abnormal Tc-99m sestamibi GSPECT vs. Normal GSPECT was evaluated on cardiac events (HR 46.1, 95% CI 7.1-46.7, p=<0.001). Abnormal Tc-99m sestamibi GSPECT independently predicted cardiac events in asymptomatic ESRD patients on hemodialysis (HR 46.1; 95% CI 7.1-46.7; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: